Researchers at Children’s Hospital of Philadelphia (CHOP) demonstrated a promising new approach in the fight against high-risk neuroblastoma, a common and potentially deadly childhood cancer that can occur within the peripheral nervous system. The study, recently published in Nature Communications, found that chimeric antigen receptor (CAR) T-cell therapy targeting two markers on neuroblastoma cancer cells simultaneously boosted overall immune response by engaging adaptive and innate immunity in preclinical models.

Dr. Christopher Cielo, Director of CHOP’s Sleep Center, was featured on Fox29 Philadelphia offering tips on getting children back on a sleep schedule for the new school year.

New findings could guide studies for future therapeutic options for patients

Get information about four aspects of COVID-19 and the vaccine to consider when deciding about getting booster doses.

When it comes to making discoveries in rare diseases, the more patients and researchers involved, the better the chances of finding breakthroughs.

Curing Anthony’s congenital hyperinsulinism was aided by a diagnostic test pioneered at CHOP 20 years ago.

Preclinical model has already revealed two drugs that could be repurposed for treatment.

Dr. Lori Handy offers 3 keys to keeping viruses out of your house this holiday season.

Find out about a webinar related to preparing for fall viral season and listen to a podcast about the importance of HPV vaccination.

Find a summary of recent updates to the Red Book, a valuable resource for healthcare providers.